In summary, we demonstrated that SIRPα-αCD123 antibodies specifically target LSCs, mediate their efficient clearance and stimulate phagocytosis of AML while restricting CD47-related on-target off-leukaemia toxicity. Here, CD47 is linked to leukemia.